Regencell Bioscience Holdings Limited (RGC) Stock Score, Valuation & Financial Research

Regencell Bioscience Holdings Limited is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for RGC

Regencell Bioscience Holdings Limited does not currently have a complete Wall Street Score. The stored market price is USD 8.11. These figures are a research snapshot, not a buy or sell recommendation.

What Regencell Bioscience Holdings Limited does

Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.

Company business and revenue

Research reporting period: 2025-06-30. A research update is not a new financial filing.

How the company makes money

Regencell Bioscience is an early-stage bioscience company that focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD. The company generates no revenue as it is currently in the development stage with no approved products, relying on capital from equity offerings to fund its research and operational expenses.

Products and services

The company is developing proprietary Traditional Chinese Medicine (TCM) formulations for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD).

Suppliers, materials and equipment

TCM Practitioner — The company sources TCM formulas and research from a TCM practitioner, with all resulting intellectual property being the exclusive property of the company. Source

Business relationships and partnerships

Honor Epic Enterprises Limited — Joint venture partner for the formation of Regencell Bioscience Asia Limited, in which the company holds a 60% equity interest. Source

Business strengths to evaluate

Proprietary TCM formulations for neurocognitive disorders Source

Business risks and research considerations

Early-stage company with limited operating history and no currently approved products Source
History of net losses and expectation of future losses Source

Sources: Company research source · Honor Epic Enterprises Limited

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

RGC financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:: Not currently available
Stored price:: USD 8.11
Market capitalization:: 4.02B (currency not supplied)
Revenue:: USD 0.00
Net income:: USD -15.29M
Free cash flow:: USD -7.7M
Cash:: USD 14.19M
Total debt:: USD 295.81K
EPS:: USD -0.03

What stands out

Free cash flow is USD -7.7M, negative for the stored period.
The balance sheet shows USD 14.19M of cash versus USD 295.81K of total debt, an excess of cash over debt on these two reported measures.
The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

Cash exceeds debt by USD 13.9M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for RGC

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

How long can RGC fund negative free cash flow using its current cash position before it may need more debt or new shares?
How is RGC likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
What specifically needs to improve for RGC to reach sustainable profitability?
What does the current fundamental change risk warning mean for the reliability or interpretation of RGC's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-15.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research RGC

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.